Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
Type:
Application
Filed:
January 17, 2024
Publication date:
May 16, 2024
Inventors:
Hilde STEINEGER, David Alan FRASER, Tore SKJÆRET
Abstract: Provided is a dosage form comprising magnesium threonate having enhanced efficacy. Also provided is a pharmacokinetic profile of magnesium threonate having enhanced efficacy. The dosage forms and pharmacokinetic profile of magnesium threonate are used to treat a variety of diseases, disorders, syndromes and/or conditions.
Type:
Application
Filed:
June 15, 2023
Publication date:
May 16, 2024
Inventors:
Guosong LIU, Fei MAO, Jason Gregory WEINGER
Abstract: The present invention aims to provide a corosolic acid-containing beverage with an increased solubility of corosolic acid in water and a method of producing the same. The present invention relates to a corosolic acid-containing beverage that is a beverage containing corosolic acid, the beverage containing: at least one type of epicatechin compound selected from the group consisting of epicatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate, wherein a corosolic acid content is 1 ppm or higher and corosolic acid is at least partially dissolved in the beverage.
Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Abstract: A method of treating cancer in a subject in need thereof includes administering to the subject an agent that inhibits uracil-DNA glycosylase wherein the agent binds to UDG such that the UDG is maintained in a destabilized, open precatalytic glycosylase conformation that prevents active site closing for functional DNA binding and nuclease flipping needed to excise damaged bases binding in DNA.
Abstract: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.
Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
Type:
Application
Filed:
January 19, 2024
Publication date:
May 16, 2024
Applicant:
Alcresta Therapeutics, Inc.
Inventors:
Robert GALLOTTO, Greta L. LORING, Kenneth GARY, Edward S. PARK, David J. BROWN, Willem Robert Klaas SCHOEVAART, Michiel Christian Alexander van VLIET
Abstract: The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the ?-position, and further comprising an ?-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.
Type:
Application
Filed:
January 22, 2024
Publication date:
May 16, 2024
Inventors:
Hilde STEINEGER, David Alan FRASER, Tore SKJÆRET
Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of short chain fatty acids, chlorogenic acid, and, optionally, ketones are disclosed. The compositions include one or more short chain fatty acids (such as butyric acid, butyrate salts, propionic acid, propionate salts, acetic acid, or acetate salts); chlorogenic acid; and, optionally, one or more beta-hydroxybutyrate salts. The compositions and methods are useful for inducing ketosis and/or beta-oxidative activity in a subject. In addition, compositions that include concentrated forms of, and methods of using, chlorogenic acid (alone or in combination with short chain fatty acids and ketones) to induce ketogenesis in a subject are disclosed.
Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.
Type:
Application
Filed:
January 25, 2024
Publication date:
May 16, 2024
Inventors:
DANIEL M. CANAFAX, WILLIAM W. XIANG, LEONARD BLUM, JIA-NING XIANG
Abstract: A method for increasing the decanoic acid concentration in the peripheral blood and to deliver decanoic acid effective for manifesting a physiological action in the peripheral tissues without a large amount of MCT being ingested at one time. A method for increasing the blood decanoic acid concentration through ingestion of a triglyceride having, as constituent fatty acids, decanoic acid and long-chain fatty acids; a blood-decanoic-acid-concentration-increasing agent in which a triglyceride having, as constituent fatty acids, decanoic acid and long-chain fatty acids is employed as an active ingredient; and a pharmaceutical composition and a food composition that contain the blood-decanoic-acid-concentration-increasing agent.
Abstract: A composition containing a docetaxel albumin nanoparticle. The composition contains docetaxel and an acid-denatured albumin, wherein the acid-denatured albumin is obtained by means of adding an acid to human serum albumin to adjust the pH value. The composition can be prepared into an injection or a freeze-dried powder injection. A composition with satisfactory physical and chemical stability is obtained by means of controlling the content of sodium octanoate in human serum albumin, preferably in an acid denaturation condition.
Type:
Application
Filed:
March 4, 2022
Publication date:
May 16, 2024
Inventors:
Chunlei LI, Xiaojun ZHANG, Yuanyuan ZHAO, Dongjian CHEN, Min LIANG, Qianbin XING, Nan LI, Yun SHU
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Application
Filed:
January 18, 2024
Publication date:
May 16, 2024
Inventors:
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: Described herein are compositions and methods for treating P. falciparum malaria by specifically activating apoptosis in cells that express PfGARP without activating apoptosis in subject host cells or parasite cells that do not express PfGARP.
Type:
Application
Filed:
February 28, 2022
Publication date:
May 16, 2024
Inventors:
Jonathan Kurtis, Andrew V. Oleinikov, Dipak K. Raj
Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
Type:
Application
Filed:
January 19, 2024
Publication date:
May 16, 2024
Inventors:
Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
Abstract: The present invention relates to a compound of formula (I) for use in a method for treating hepatic portal/periportal inflammation, optionally hepatic portal/periportal fibrosis.
Type:
Application
Filed:
October 16, 2020
Publication date:
May 16, 2024
Inventors:
RAPHAËL DARTEIL, ERIC MELDRUM, JACKY VONDERSCHER
Abstract: Disclosed herein are methods for treating hyperparathyroidism, osteoporosis, or cancer cachexia, or inhibiting abnormally increased white adipose tissue browning, or decreasing the risk of a kidney stone in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a negative allosteric modulator of parathyroid hormone (PTH) type 1 receptor (PTHR) signaling.
Type:
Application
Filed:
March 9, 2022
Publication date:
May 16, 2024
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Abstract: The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.
Type:
Application
Filed:
November 17, 2023
Publication date:
May 16, 2024
Applicant:
Axial Therapeutics, Inc.
Inventors:
Christopher J. Oalmann, Dennis S. Yamashita, Patrick J. Stern
Abstract: Provided is a therapeutic agent for cellular drug resistance to a microtubule inhibitor. The therapeutic agent contains a ? opioid receptor agonist.
Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindo1-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
Type:
Application
Filed:
December 19, 2023
Publication date:
May 16, 2024
Applicant:
Siga Technologies, Inc.
Inventors:
Shanthakumar R. TYAVANAGIMATT, Melialani A.C.L.S. ANDERSON, William C. WEIMERS, Dylan NELSON, Tove' C. BOLKEN, Dennis E. HRUBY, Michael H. O'NEILL, Gary SWEETAPPLE, Kelley A. McCLOUGHAN
Abstract: Provided herein are compositions suitable for treating chemically induced eye damage comprising (a) a nonsteroidal anti-inflammatory drug (NSAID), (b) a histone deacetylase (HDAC) inhibitor and (c) an angiotensin converting enzyme (ACE) inhibitor and, optionally, (d) a water-soluble vitamin. Methods of using provided compositions to treat ocular toxicity and corneal damage following exposure to chemical agents (e.g., mustard gas) are also provided.
Type:
Application
Filed:
December 20, 2023
Publication date:
May 16, 2024
Applicants:
The Curators of the University of Missouri, The United States Government as Represented by the Department of Veterans Affairs
Abstract: The present invention aims to provide a composition for improving a blood cholesterol level and a method of improving a blood cholesterol level. The present invention relates to a composition for improving a human blood cholesterol level, which contains L-ergothioneine or a salt thereof as an active ingredient.
Abstract: The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.
Abstract: In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Type:
Application
Filed:
December 19, 2023
Publication date:
May 16, 2024
Inventors:
John Gunn, Laura Kuo, Christian Melander, William M. Huggins
Abstract: An oral feline feed and a method of controlling fleas in a feline in need thereof by orally administering to the feline a daily feed comprising an effective amount of an isoxazoline for an effective time to thereby cause the amount of isoxazoline in the feline's blood to rise to and maintain at a therapeutically effective level for controlling fleas.
Type:
Application
Filed:
December 18, 2023
Publication date:
May 16, 2024
Inventors:
Robin S. Readnour, Kevin E. Willard, Joseph R. Winkle
Abstract: The present disclosure provides, inter alia, a compound having the structure: Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, methods for treating or ameliorating the effects of a neurodegenerative disease, methods for alleviating side effects in a subject undergoing radiotherapy and/or immunotherapy, and methods for treating or ameliorating the effects of an infection associated with ferroptosis in a subject.
Type:
Application
Filed:
November 24, 2023
Publication date:
May 16, 2024
Inventors:
Brent R. STOCKWELL, Arie ZASK, Hui TAN, Jacob D. DANIELS
Abstract: In some embodiments, a method of treating spinal cord injury or damage, or a complication thereof, in a patient is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I, Ia, Ik, or II.
Type:
Application
Filed:
February 18, 2022
Publication date:
May 16, 2024
Inventors:
Stella T. Sarraf, Vincent F. Simmon, Peter W. Vanderklish
Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
Abstract: The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Type:
Application
Filed:
January 12, 2024
Publication date:
May 16, 2024
Inventors:
Sean Cunningham, Seamus Mulligan, Michael Myers
Abstract: The present invention provides a pharmaceutical composition for the treatment or prevention of stress-related disorders, stress-induced anxiety disorders, or stress-related disorders or anxiety disorders associated with depression, the composition containing a selective ?-opioid receptor agonist as an active component, wherein the selective ?-opioid receptor agonist preferably also has a ?-opioid receptor antagonist action and a ?-opioid receptor antagonist action.
Type:
Application
Filed:
February 25, 2022
Publication date:
May 16, 2024
Applicants:
TOKYO UNIVERSITY OF SCIENCE FOUNDATION, NIPPON CHEMIPHAR CO., LTD.
Abstract: A pharmaceutical composition can include a lipophilic oil. The pharmaceutical composition can further include an analgesic agent, anesthetic agent, anti-inflammatory agent, or a mixture thereof dispersed in the lipophilic oil. The pharmaceutical composition can further include a structuring agent at least a portion of which is not dissolved in the lipophilic oil and forms a gel.
Type:
Application
Filed:
January 25, 2024
Publication date:
May 16, 2024
Inventors:
Brett Hale Davis, Caleb Adrian Lade, Sierra Nichelle Erickson, Susan Alice Wojtalewicz
Abstract: Embodiments of the present disclosure relate to methods of using bupivacaine multivesicular liposomes as stellate ganglion block for treating or ameliorating an anxiety disorder or a traumatic brain injury associated with overactive or unbalanced sympathetic nervous system, including but not limited to, generalized anxiety disorders, panic disorder, and post-traumatic stress disorder.
Type:
Application
Filed:
November 7, 2023
Publication date:
May 16, 2024
Inventors:
John Spranger, Roy Winston, Jonathan Slonin
Abstract: The present invention relates to methods for treating a disease or disorder associated with EP300 dependency and elevated CRBN expression levels (e.g., cancer (e.g., neuroblastoma)).
Abstract: This disclosure relates to the identification of a subset of mGluR network gene CNVs that are predictive of efficacy of treatment with fasoracetam, as well as the identification of an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD as well as having certain symptoms associated with ADHD.
Type:
Application
Filed:
June 7, 2023
Publication date:
May 16, 2024
Applicant:
The Children's Hospital of Philadelphia
Inventors:
Garry A. Neil, Liza Squires, Hakon Hakonarson
Abstract: Provided herein are methods of treating a disorder ameliorated by activating muscarinic receptors in a patient 55 years or older in need thereof. The method comprises administering a total daily dose of between 25 and 200 mg xanomeline and/or a salt thereof and between 5 and 30 mg of a salt of trospium to the patient, such as a total daily dose of between 100 and 200 mg xanomeline and/or a salt thereof and between 20 and 30 mg of a salt of trospium. The present disclosure also provides a method for treating dementia-related psychosis and a method decreasing the risk of relapse in a patient having dementia-related psychosis.
Type:
Application
Filed:
August 23, 2023
Publication date:
May 16, 2024
Inventors:
Andrew MILLER, Stephen BRANNAN, Inderjit KAUL, Ronald N. MARCUS, David S. SMALL
Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
Abstract: The present invention relates to a compound for inhibition of nonsense-mediated mRNA decay (hereinafter referred to as “NMD”) or a pharmaceutically acceptable salt thereof. The present invention aims to prevent or treat NMD-related disease through the NMD-inhibiting compound.
Abstract: Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone, having the chemical structure illustrated as Suitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration.
Type:
Application
Filed:
October 27, 2023
Publication date:
May 16, 2024
Applicant:
Corcept Therapeutics Incorporated
Inventors:
Grace Mann, Iulia Cristina Tudor, William Guyer, Hazel Hunt, Joseph Custodio
Abstract: Methods for treating a cancer patient with a neutrophil-to-lymphocyte ratio (NLR) greater than 3 are disclosed, comprising administering a nonsteroidal glucocorticoid receptor antagonist (GRA) to such a cancer patient, effective to reduce the patient's NLR. The methods include administering a nonsteroidal GRA and a cancer treatment to such a cancer patient, effective to reduce the patient's NLR and enhance the treatment of the cancer patient. The GRA may be orally administered. The nonsteroidal GRA may be a nonsteroidal compound comprising a heteroaryl ketone fused azadecalin structure (e.g., relacorilant) or an octahydro fused azadecalin structure (e.g., exicorilant). The cancer treatment may include chemotherapy, immunotherapy, radiation therapy, administration of an anti-angiogenic agent, administration of a growth factor inhibitor, and surgery.
Type:
Application
Filed:
October 14, 2020
Publication date:
May 16, 2024
Applicant:
Corcept Therapeutics Incorporated
Inventors:
Andrew Greenstein, Lawrence Lu, Joseph Custodio, Stacie Shepherd
Abstract: The present invention is directed to improved methods, formulations, and compositions employing substituted camptothecins such as, but not limited to, irinotecan and topotecan as well as analogs, derivatives, and prodrugs thereof. These methods, formulations, and compositions can be used to treat malignancies and other diseases and conditions including, but not limited to, non-malignant proliferative disorders, infections, inflammatory, and immunological diseases.
Abstract: The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.
Type:
Application
Filed:
September 25, 2023
Publication date:
May 16, 2024
Applicant:
BioDelivery Sciences International, Inc.